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Acromegaly is a hormonal disorder caused by a growth
hormone (GH)-secreting pituitary tumor. It commonly
appears in middle-age and, because of its slow develop-
ment, is often overlooked. In the West, the prevalence is
approximately 60 cases per million population. The term
itself refers to abnormal growth in the hands and feet,
although enlargement of the head—especially the mandi-
ble—is also typical. Cardiac disease occurs in about one-
third of patients and is associated with a twofold increase in
their risk of death from heart disease, which includes
cardiomyopathy, arrhythmia, left ventricular hypertrophy,
decreased diastolic function, or hypertension [1]. Here, we
report a case of hypertensive acromegaly with ST-segment
elevation acute myocardial infarction. Acromegaly was
diagnosed during admission, and the patient received
successful primary transluminal coronary angioplasty.
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Acromegaly is a disorder caused by the excess production of pituitary growth hormone and is characterized
by the enlargement of the hands, feet and head. Increased morbidity and mortality with acromegaly is
associated with cardiovascular complications, hypertension, glucose intolerance, cardiomyopathy and
coronary artery disease. We report a case of acromegaly, which presented with ST-segment elevation acute
myocardial infarction. The patient received successful primary transluminal coronary angioplasty with
stent implantation. Acromegaly was suspected from typical appearance, and confirmed with hormonal
examination and imaging of the pituitary mass. We discuss this case in comparison with previous literature.
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CASE REPORT
A 71-year-old female with a 20-year history of controlled
hypertension was admitted with abrupt anterior chest
tightness together with diaphoresis and nausea. Chest
pain was described as an oppressive sensation, radiating
bilaterally to the shoulders and lasting > 30 minutes. Vital
signs on arrival in the emergency room were blood pressure
149/96 mmHg, pulse rate 88/min, respiratory rate 18/min,
and body temperature 36.5°C. Clear breathing, regular heart
sounds, and no murmur or S3 gallop were found on
auscultation. Twelve-lead electrocardiography revealed V1–
V2 ST-segment elevation and frequent ventricular premature
contractions (Figure 1). Chest X-ray revealed cardiomegaly
with mild pulmonary congestion. Primary percutaneous
transluminal coronary intervention was performed for
acute ST-segment elevation myocardial infarction 7 hours
after the onset of chest tightness. We successfully performed
coronary angioplasty and stent implantation over segment
7 of the left anterior descending artery. There was no
residual stenosis in the culprit lesion. Echocardiography
showed left ventricular concentric hypertrophy and apical
akinesia. Serial cardiac enzymes were elevated.
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At admission, her large head, hands, feet, and
prognathism led us to suspect acromegaly. Comparing
her appearance with pictures taken 20 years previously,
we noted significant facial changes and acral growth. No
visual field defect was noted. We diagnosed diabetes
mellitus (fasting glucose, 179 mg/dL; HbA1C, 11%) and
hypercholesterolemia (cholesterol, 286 mg/dL; LDL-C,
147 mg/dL), together with high GH level (> 68 μIU/mL,
normal < 5 μIU/mL), high insulin-like growth factor-1
(IGF-1) level (1,092.3 U/mL, normal 0.45–2.2 U/mL),
and mild increases in prolactin (17.2 ng/mL, normal 1.4–
14.6 ng/mL). Oral glucose tolerance test confirmed a
failure to suppress GH (hGH — 0 minutes: > 68 μIU/mL;
60 minutes: > 68 μIU/mL; 120 minutes: > 68 μIU/mL).
Serum levels of other pituitary hormones were normal.
Thyroid-stimulating hormone was 0.4 μU/mL (normal,
0.25–4 μU/mL). Adrenocorticotropic hormone was
39 pg/mL (normal, 9–52 pg/mL). Cortisol was 11.8 μg/
dL (normal, 5–25 μg/dL). Follicle-stimulating hormone
was 7.1 mIU/mL (normal, < 40 mIU/mL). Estradiol was
< 20 pg/mL (normal, 0–30 pg/mL in postmenopausal
women).
Four abnormal image findings supported the diagnosis
of acromegaly. Skull X-ray revealed a suspiciously enlarged
sella turcica. Foot X-ray revealed an increase in heel pad
thickness (> 1.3 cm). Bilateral hand X-ray showed resorption
at the margins of the ungual tufts and the intracortical
regions. Brain magnetic resonance imaging (MRI) with
gadolinium enhancement showed a lobulated mass
(2 × 2.1 × 3 cm) arising from the pituitary gland with
extension to the suprasellar region. This lesion was
visualized as hypointensity in T1W1 and high T2W1 with
heterogeneous enhancement (Figure 2). Visual field defects
were tested for with perimetry and none were found.
Although transsphenoidal surgery for pituitary
macroadenoma is generally the therapy of choice, the
unstable condition of this patient immediately after acute
myocardial infarction suggested that medical therapy with
bromocriptine should be given first. After discharge, she
received regular clinical follow-up with medication, and no
subsequent chest discomfort was reported. She received
radiotherapy but refused surgery.
DISCUSSION
GH-secreting adenomas account for approximately 20% of
all pituitary tumors [2]. In these cases, adults clinically
present with acromegaly. As in the case reported here,
acromegaly is associated with a high prevalence of
cardiovascular disorders. Most of the complications and
symptoms seen in patients with acromegaly are due to the
increased production of IGF-1, a GH-dependent factor [1].
Excess GH and IGF-1 are associated with cardiac dysfunc-
tion and acromegalic cardiomyopathy [3], via a specific
derangement of cardiomyocytes, which leads to abnor-
malities in cardiac muscle structure and function, induc-
ing cardiomyopathy [4].
Endothelial dysfunction has also been identified as an
early marker of cardiovascular disease [5]. Maison et al
reported that in acromegaly, it appears that endothelium-
dependent vasodilatation is impaired, while sympathetic-
mediated vasoconstrictive response is increased [6].
However, Otsuki et al found that intima-medial thickness
(IMT), a marker of endothelial dysfunction, was lower in
Figure 2. Brain magnetic resonance imaging shows a pituitary mass
(arrow) with suprasellar extension and compression of the optic chiasma.
Figure 1. Electrocardiography showed ST-segment elevation acute
myocardial infarction.
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subjects with acromegaly than in non-acromegalic controls
matched for risk factors [7]. This suggests that in acromegaly,
IMT changes are not from GH/IGF-1 excess per se, but are
instead a secondary response to cardiovascular changes.
Nevertheless, the evidence, albeit indirect, indicates that
the endothelium changes either directly via endothelial
IGF-1 receptors, or indirectly through effects on hyper-
tension, body composition and lipid metabolism.
Three major categories of therapy are currently available
for acromegaly. These are surgery, pharmacotherapy and
radiotherapy. Transsphenoidal adenomectomy is the
general therapy of choice. Cure rates are high in micro-
adenomas, but only < 50% in macroadenomas [8]. Somato-
statin analogs induce remission in 59% of patients within
the first year of treatment. Bogazzi et al found that treat-
ment with somatostatin analogs improved intrinsic myo-
cardial contractility and cardiac fibrosis [9]. Treatment
with this GH receptor antagonist leads to a 90% remission
rate [10]. The best therapeutic prognosis is achieved
through normalization of biochemical indices [11]. Cur-
rent evidence suggests that a post-treatment random se-
rum GH < 2.5 mg/L and a normal serum IGF-1 value de-
fines biochemical cure. Available data suggest that by
achieving these GH levels, there is a related decrease in
the prevalence of chronic complications, and therefore,
improved mortality [12]. Unless GH levels are controlled,
survival is reduced by an average of 10 years compared
with an age-matched control population.
The case of a hypertensive patient suffering from acute
ST-segment elevation myocardial infarction was presented
here. Acromegaly, diabetes and hypercholesterolemia were
newly diagnosed during admission. She received successful
emergency coronary angioplasty with stent implantation.
Because of her age (71 years old) and the presence of three
coronary risk factors, it is quite possible that the acute
coronary syndrome episode was not related to acromegaly.
We located only one previous report on the anatomo-
pathologic relationship in a 54-year-old acromegaly
patient who suffered sudden cardiac death and acute
myocardial infarction [13]. Although the causality between
acute coronary syndrome and acromegaly is unclear,
acromegaly is associated with glucose intolerance and
endothelial dysfunction, two risk factors for coronary artery
disease. Whether or not high GH/IGF-1 levels contribute to
endothelial dysfunction, glucose intolerance, hypertension,
and then acute myocardial infarction should be considered.
Physicians should be alert to acromegaly by being attentive
to the patient’s appearance and realizing the association
with higher prevalence of cardiovascular morbidity and
mortality. The goals of acromegaly treatment, in addition to
reduction of tumor bulk and symptomatic relief, should
include the lowering of GH circulating concentrations to
below a critical level (2.5 μg/L, “safe” GH), normalization
of serum IGF-1 concentrations according to age, and
improvement (or at least not worsening) of comorbidities
(diabetes mellitus, hypertension, cardiomyopathy, sleep
apnea) [14]. In this way, premature mortality in acromegaly
patients may be reduced.
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